Deargen is Discovery Tools (Healthcare) in South Korea that focus on collective intelligence business. Founded in 2016. They cover business area such as developer, an Artificial Intelligence-base drug discovery platform, new drug development, rare and intractable disease, AI, collective intelligence, genome datum analysis, biomarker prediction, molecule selection, optimization, clinician, precision medicine, small molecule.
2016
( 8 years old in 2024 )
Collective Intelligence
-
6th Floor, A602, Administration B/D
193, Munji-ro
Daejeon, Yuseong-gu
South Korea
Private
developeran Artificial Intelligence-base drug discovery platformnew drug developmentrare and intractable diseaseAIcollective intelligencegenome datum analysisbiomarker predictionmolecule selectionoptimizationclinicianprecision medicinesmall molecule
* We use standard office opening hours in near Deargen's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Deargen is Discovery Tools (Healthcare) business from South Korea that founded in 2016 (8 years old in 2024), Deargen business is focusing on Collective Intelligence.
Deargen headquarter office and corporate office address is located in 6th Floor, A602, Administration B/D 193, Munji-ro Daejeon, Yuseong-gu South Korea.
Deargen was founded in South Korea.
In 2024, Deargen is currently focus on collective intelligence sector.
Above is snippet of Google Trends for "collective intelligence" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Deargen, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
